- Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million
- Received U.S. FDA approval of and launched ATEBRIOZ® for FOP
- Announced three positive
- Late-breaking Phase 3 AZURE-1 and longer-term brelovitug efficacy, safety, and deepening treatment response data highlighted across a broad HDV population, including patients with cirrhosis
- Additional Phase 2b
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will report third quarter 2026 financial results on November 3, 2026. Mirum will also host a conference call to discuss
- Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions
- Mirum plans to submit an sNDA in H1 2027 to expand the
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences:
Wolfe Research Healthcare Conference 2026: Tuesday,
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on October 9, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of
- Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p<0.0001)
- In patients with
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the
– Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24
– 48-week data from Phase 2b portion of AZURE-1 demonstrate deepening viral suppression and increased rates
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP
-Atebrioz expected to be available in the United States in October
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on September 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced the appointment of Rob Myers, M.D., as Chief Medical Officer, effective September 21, 2026. Dr. Myers will join the company’s
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on August 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of
- Q2 2026 net product sales of $176 million
- 2026 net product sales guidance increased to $680 million to $700 million
- Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus
